Proceed Safely with Thrombate III

Therapeutic Overview

At least 60,000 people in the United States (U.S.) have hereditary antithrombin (AT) deficiency.1 This condition puts patients at risk of developing venous thromboembolism (VTE). In fact, 250,000 patients are hospitalized for VTE each year in the U.S. and it’s estimated that as many as 7500 or 3% of these individuals have hereditary antithrombin deficiency.2,3

Thrombate III Prevents Thromboembolism in High-risk Situations

Thrombate III is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.4

Thrombate III—treating hereditary antithrombin deficiency for more than 16 years.6

References:

  1. US Census Bureau, Population Division. US and World Population Clocks – POPClocks. http://www.census.gov/main/www/popclock.html. Revised November 22, 2006. Updated January 31, 2008. Accessed April 9, 2009.
  2. Rosamond W, Flegal K, Furie K, et al; for American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117(4):e25-e146.
  3. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006;43(3):249-290.
  4. Thrombate III [prescribing information]. Research Triangle Park, NC: Talecris Biotherapeutics, Inc.; 2008.
  5. Data on file, Talecris Biotherapeutics, Inc., 1988.
  6. Scott GR, Robinson MJ, Wilczek J, Berson MR. FDA Drug and Device Product Approvals. Springfield, VA: Division of Drug Information Resources, OM, CDER, US Dept of Health and Human Services, Public Health Service; 1991;14(2):333.

Important Safety Information

Thrombate III is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and foul taste in the mouth.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.

Please speak to your doctor and refer to Thrombate III Prescribing Information for full details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.